US Patent

US11426407 — Modulators of cystic fibrosis transmembrane conductance regulator

Method of Use · Assigned to Vertex Pharmaceuticals Inc · Expires 2035-10-06 · 9y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a compound and its pharmaceutical compositions for treating diseases caused by the CFTR protein, such as cystic fibrosis.

USPTO Abstract

The present invention features a compound of formula I:or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3425`	—
`U-3425`	—
`U-3595`	—
`U-3595`	—

Patent Metadata

Patent number: US11426407
Jurisdiction: US
Classification: Method of Use
Expires: 2035-10-06
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Vertex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.